Cell-mediated immune responses to COPV early proteins

被引:24
作者
Jain, Suchitra
Moore, Richard A.
Anderson, Davina M.
Gough, Gerald W.
Stanley, Margaret A.
机构
[1] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England
[2] GlaxoSmithKline, Med Res Ctr, Stevenage SG1 2NY, Herts, England
关键词
COPV; vaccines; E1; E2; early proteins; cell-mediated immunity; lymphoproliferation; IFN-gamma ELISPOT; DTH; mucosal immunization;
D O I
10.1016/j.virol.2006.07.032
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Cell-mediated immunity plays a key role in the regression of papillomavirus-induced warts and intra-epithelial lesions but the target antigens that induce this response are not clear. Canine oral papillomavirus (COPV) infection of the oral cavity in dogs is a well-characterized model of mucosal papillomavirus infection that permits analysis of the immune events during the infectious cycle. In this study we show that during the COPV infectious cycle, systemic T cell responses to peptides of several early proteins particularly the E2 protein, as assayed by delayed type hypersensitivity, lymphoproliferation and IFN-gamma ELISPOT, can be detected. The maximal response occurs in a narrow time window that coincides with maximal viral DNA replication and wart regression: thereafter, systemic T cell responses to early proteins decline quite rapidly. Vaccination using particle-mediated immunotherapeutic delivery (PMID) of codon-modified COPV E2 and El genes induces strong antigen-specific cell-mediated immune responses in the vaccinated animals. These data show that therapeutic immunization by PMID with codon-modified E2 is completely effective, that to E1 is partially protective, that this correlates with the intensity of antigen-specific cell-mediated immune responses and, further. they emphasize the importance of these responses and the route of immunization in the generation of protective immunity. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:23 / 34
页数:12
相关论文
共 48 条
[1]  
André S, 1998, J VIROL, V72, P1497
[2]  
[Anonymous], PAPILLOMAVIRUS REV C
[3]  
Baldwin PJ, 2003, CLIN CANCER RES, V9, P5205
[4]   Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia [J].
Bontkes, HJ ;
de Gruijl, TD ;
Bijl, A ;
Verheijen, RHM ;
Meijer, CJLM ;
Scheper, RJ ;
Stern, PL ;
Burns, JE ;
Maitland, NJ ;
Walboomers, JMM .
JOURNAL OF GENERAL VIROLOGY, 1999, 80 :2453-2459
[5]   Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection [J].
Brandsma, JL ;
Shlyankevich, M ;
Zhang, LX ;
Slade, MD ;
Goodwin, EC ;
Peh, W ;
Deisseroth, AB .
JOURNAL OF VIROLOGY, 2004, 78 (01) :116-123
[6]   Vaccination against papillomavirus in cattle [J].
Campo, MS .
CLINICS IN DERMATOLOGY, 1997, 15 (02) :275-283
[7]   Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection [J].
Carter, JJ ;
Koutsky, LA ;
Hughes, JP ;
Lee, SK ;
Kuypers, J ;
Kiviat, N ;
Galloway, DA .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (06) :1911-1919
[8]   HUMORAL IMMUNE-RESPONSE TO THE E7 PROTEIN OF BOVINE PAPILLOMAVIRUS TYPE-4 AND IDENTIFICATION OF B-CELL EPITOPES [J].
CHANDRACHUD, LM ;
ONEIL, BW ;
JARRETT, WFH ;
GRINDLAY, GJ ;
MCGARVIE, GM ;
CAMPO, MS .
VIROLOGY, 1994, 200 (01) :98-104
[9]   Carcinogenicity of human papillomaviruses [J].
Cogliano, V ;
Baan, R ;
Straif, K ;
Grosse, Y ;
Secretan, B ;
El Ghissassi, F .
LANCET ONCOLOGY, 2005, 6 (04) :204-204
[10]   IMMUNOLOGICAL EVENTS IN REGRESSING GENITAL WARTS [J].
COLEMAN, N ;
BIRLEY, HDL ;
RENTON, AM ;
HANNA, NF ;
RYAIT, BK ;
BYRNE, M ;
TAYLORROBINSON, D ;
STANLEY, MA .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1994, 102 (06) :768-774